Comments
Aurobindo Pharma said on Monday its arm Aurobindo Pharma USA Inc has signed a pact to acquire an under-development product and certain related assets from Australian Advent Pharmaceuticals Pty Ltd for $ 12.5 million.
The company’s wholly owned subsidiary, Aurobindo Pharma USA Inc, has entered into an agreement to acquire a product under development and related assets from Advent Pharmaceuticals Pty Ltd, Australia, through its subsidiary AuroScience Pty Ltd Melbourne, Aurobindo Pharma said in a filing to BSE.
The acquisition is for a cash consideration of $ 12.5 million, it added. The indicative time period for completion of the acquisition is January 2019, Aurobindo Pharma said.
The acquisition provides an opportunity to acquire assets that would be used for speciality generics business, it added.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.